 | |
| Clinical data | |
|---|---|
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H22N4O2 |
| Molar mass | 314.389 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Resiquimod (R-848) is a drug that acts as an immune response modifier, and hasantiviral andantitumour activity. It is used as atopical gel[1] in the treatment of skin lesions[2] such as those caused by theherpes simplex virus[3][4] andcutaneous T cell lymphoma,[5] and as an adjuvant to increase the effectiveness ofvaccines.[6] In ananimal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates tocancer immunotherapy with acheckpoint inhibitor through stimulation of tumor-associated macrophages.[7] It has several mechanisms of action, being both anagonist fortoll-like receptor 7 and8,[8] and an upregulator of theopioid growth factor receptor.[9]On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.[10]
 | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |
 | Thisdermatologicdrug article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
